|Description||DBeQ inhibits p97 competitively with respect to ATP, with Ki of 3.2 μM, suggesting that it binds to the active site of the D2 domain.|
|B0084-463451||50 mg||$198||In stock|
CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in ...
NMS-873 is a potent, selective allosteric VCP/p97 inhibitor with IC50 value of 30 nM.
ML240, a quinazoline derivative, has been found to be a p97 ATPase inhibitor and probably be effective against colon cancer and show antiproliferative activity ...
This active molecular is a selective p97 inhibitor. The IC50 value of it decreased with increasing ATP concentration. IC50 value is 26.0 ± 0.9μM in 5μM ATP, 11....
DBeQ inhibits p97 competitively with respect to ATP, with Ki of 3.2 μM, suggesting that it binds to the active site of the D2 domain.
NMS-859 is very selective (IC50 >10 μM) against all of the AAA ATPases, HSP90 or the 53 kinases tested. NMS-859 was active in a cell proliferation assay, with I...
ML241 is identified as a potent and selective inhibitors of p97 ATPase (IC(50)= 100 nM). ML241 inhibits degradation of a p97-dependent but not a p97-independent...